Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

Recent & Breaking News (TSX:GUD)

Synergy CHC Corp. Announces Second Quarter 2017 Results

Marketwired August 14, 2017

Knight Supports Crescita Trajectory

MarketWire Canada August 14, 2017

Knight Reports Second Quarter 2017 Results

MarketWire Canada August 10, 2017

Knight Supports Synergy with Third Secured Loan

MarketWire Canada August 9, 2017

Notice of Knight Therapeutics' Second Quarter 2017 Results Conference Call

Marketwired August 3, 2017

Braeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE(R) in Canada for Opioid Drug Dependence

MarketWire Canada June 13, 2017

Knight to Present at the Jefferies Global Healthcare Conference in New York City

Marketwired June 2, 2017

Knight to Present at the National Bank Financial Quebec Conference in Toronto

Marketwired May 31, 2017

Knight Reports First Quarter 2017 Results

MarketWire Canada May 11, 2017

Knight Therapeutics Inc. announces voting results from the Annual Meeting

MarketWire Canada May 10, 2017

Notice of Knight Therapeutics' First Quarter 2017 Results Conference Call

Marketwired May 4, 2017

Synergy CHC Corp. Announces Private Placement Offering of up to US$20 Million

Marketwired May 3, 2017

Knight to Present at the 2017 Bloom Burton & Co. Healthcare Investor Conference in Toronto

Marketwired April 25, 2017

Knight Rewarded for Doing Pro Bono

Marketwired March 28, 2017

Knight Reports Fourth Quarter and Year-Ended December 31, 2016 Results

Marketwired March 16, 2017

Knight Therapeutics Announces the Canadian commercialization of MOVANTIK®

MarketWire Canada March 13, 2017

Notice of Knight Therapeutics' Fourth Quarter and Year Ended December 31, 2016 Results Conference Call

MarketWire Canada March 10, 2017

Knight Therapeutics Inc. Announces Board Change

MarketWire Canada February 23, 2017

Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien(R) in Canada

MarketWire Canada February 22, 2017

Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien® in Canada

GlobeNewswire February 22, 2017